DMP-1/500
Description
- Combination therapy for effective management of type 2 diabetes
- Glimepiride (1 mg): Enhances insulin secretion from pancreatic β-cells
- Metformin (500 mg): Reduces hepatic glucose production and improves insulin sensitivity
- Helps control both fasting and post-meal blood glucose levels
- May assist in mild weight loss or weight neutrality
- Generally well-tolerated and suitable for long-term use
- To be taken with meals to minimize gastrointestinal side effects
Composition
Glimepiride 1 mg + Pioglitazone 15 mg + Metformin (Extended Release) 500 mg
Benefits
DMP-1/500 offers a comprehensive and synergistic approach to diabetes management by targeting multiple defects in glucose regulation. It effectively reduces fasting and postprandial blood glucose levels, improves insulin sensitivity, and decreases insulin resistance. The extended-release form of Metformin provides consistent blood sugar control with fewer gastrointestinal side effects. This combination helps in preventing diabetes-related complications, improving metabolic health, and reducing the risk of cardiovascular events in patients with type 2 diabetes who do not respond adequately to monotherapy or dual therapy.
Introduction
DMP-1/500 is a triple-combination oral antidiabetic medication that brings together the complementary actions of Glimepiride, Pioglitazone, and Metformin (ER) to achieve superior glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, enhances insulin secretion; Pioglitazone, a thiazolidinedione, improves peripheral insulin sensitivity; and Metformin (ER), a biguanide, reduces hepatic glucose production while increasing insulin action. This extended-release formulation ensures sustained glucose control throughout the day and is especially suitable for patients who require multidrug therapy for optimal blood sugar management.
